AstraZeneca
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Pfizer has transferred an AAV capsid designed for a rare neurological disease target to AstraZeneca’s rare disease subsidiary, Alexion, as ...
FDA Approves Keytruda for Biliary Cancer, Rivals AstraZeneca’s Imfinzi
Merck’s Keytruda has received FDA approval to treat locally advanced unresectable or metastatic biliary tract cancer, alongside gemcitabine and cisplatin ...
AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture
AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...
Klick Health Welcomes Ellen Cappellino, Former AstraZeneca and Vertex Executive, as Value, Access, and Reimbursement Director
Klick Health, a prominent healthcare marketing agency, has recently appointed Ellen Cappellino, a distinguished figure in the pharmaceutical industry, to ...
Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph
At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...
AstraZenecaās nasal flu vaccine nears FDA approval
AstraZeneca’s FluMist, a nasal spray flu vaccine with a two-decade history, is poised to potentially become available for self-administration as ...
RSV outbreak causes shortage of Sanofi, AZās Beyfortus
Shortly after Sanofi and AstraZeneca secured a significant FDA approval for their respiratory syncytial virus (RSV) antibody, Beyfortus, the highly ...
Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)
ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...
Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)
ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
Zilbrysq, A Complement C5 Inhibitor For Myasthenia Gravis, Gets FDA Approval As UCB’s Second Drug For The Rare Disease
UCB is celebrating an impressive streak of FDA approvals, securing the green light for both the plaque psoriasis treatment Bimzelx ...
J&Jās drug combo challenges AZās Tagrisso in lung cancer, but faces hurdles
In a high-stakes battle, Johnson & Johnson’s drug combination of Rybrevant and the Lazertinib, developed in partnership with Yuhan, has ...
AstraZenecaās Tagrisso dominates lung cancer market with projected $7B sales by 2025
The lung cancer drug market has been notably dominated by antibodies and immunotherapies, but a recent report from GlobalData suggests ...
AstraZeneca Settles Nexium, Prilosec Lawsuits for $425M
AstraZeneca has agreed to pay Ā£352 million ($425 million) to settle approximately 11,000 personal injury lawsuits in New Jersey and ...
Novartisā iptacopan impresses in phase 3 trial for rare kidney disease
Novartis is celebrating a significant achievement as its investigational oral factor B inhibitor reaches a crucial milestone in a phase ...
AstraZeneca fined for misleading Symbicort ads that endangered patientsā health
In a startling turn of events, AstraZeneca finds itself entangled in a web of controversy as it faces stern scrutiny ...
Big Pharma agrees to negotiate drug prices with Medicare: What does it mean for patients and taxpayers?
Following the recent disclosure by the Centers for Medicare & Medicaid Services (CMS) regarding the list of drugs slated for ...
Big Pharmaās stance on CMS drug price negotiations remains unclear
Following the release of the list of drugs slated for pricing negotiations under the Inflation Reduction Act (IRA) by the ...
NICE rejects Enhertu for HER2-low breast cancer over cost concerns
The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
How Tezspire helps a punk rocker with severe asthma live his life to the fullest
Amgen and AstraZeneca are making a triumphant return to television advertising to highlight how Tezspire is transforming the lives of ...
Alexion settles Soliris sales practices lawsuit for $125 million
After nearly seven years since the departure of Alexion’s CEO and CFO amidst an investigation into improper sales practices, the ...
Moderna axes four programs, including two former AstraZeneca collaborations
Moderna, following its recent phase 3 success with an mRNA flu vaccine, has made the decision to remove four clinical ...
Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)
Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...
Fasenra, a new treatment for EGPA, achieved remission in Phase III trial (IASLC WCLC 2023 Conference)
The MANDARA Phase III trial has shed new light on the effectiveness of AstraZeneca’s Fasenra (benralizumab). Unveiling favorable high-tier outcomes, ...
New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)
The International Association for the Study of Lung Cancer (IASLC) presented pivotal results from the DESTINY-Lung02 Phase II trial at ...
AstraZeneca and Verge partner to discover AI-driven drugs for rare neurodegenerative diseases
Verge Genomics is expanding its roster of Big Pharma partnerships by teaming up with AstraZeneca in a substantial $42 million ...
J&Jās Rybrevant Beats Chemo In Lung Cancer Patients Who Failed Tagrisso
The medical community buzzed with anticipation when Johnson & Johnson (J&J) released information about Rybrevant, their latest drug venture into ...
Astrazeneca Suffers Setback As FDA Rejects Ultomiris For Rare Autoimmune Disease
AstraZeneca’s plans to expand the use of Ultomiris in the United States have encountered a setback, as the FDA issued ...
CanSino Biologics eyes more mRNA vaccine deals after AstraZeneca pact
CanSino’s recent collaboration with AstraZeneca in mRNA manufacturing is just the beginning of their ambitions in this field, according to ...
